Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.

Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing PPCI.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04785209

Enrollment

640

Registered

2021-03-05

Start date

2020-09-01

Completion date

2024-05-01

Last updated

2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No-Reflow Phenomenon

Brief summary

Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores

Interventions

OTHERMean platelet volume, lymphocyte number, STEMI clinical risk scores

Lab parameters

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Inclusion criteria

* patients presenting with acute STEMI, within 24 hours of symptoms, fulfilling criteria for PPCI protocol in our facility

Exclusion criteria

* patients presenting more than 24 hours of symptoms onset * patients not eligible for PPCI program in our facility

Design outcomes

Primary

Measure	Time frame	Description
Number of participents with No reflow after PPCI and in hospital mortality	Within 48 hours from admission	No reflow: suboptimal myocardial reperfusion through a part of coronary circulation without angiographic evidence of mechanical vessel obstruction. In hospital mortality

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026